The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- Mediterranean-style diet may be linked to lower odds of developing MS
- Guest Voice: How phototherapy helped me reclaim my life with MS
- B-cell depletion therapy recruits gut cells to fight MS, study suggests
- Stem cell treatment for progressive MS shows potential to protect the brain
- Study uses lab-grown ‘mini brains’ to explore myelin repair in MS